Introduction {#sec1-1759091417745426}
============

The axon initial segment (AIS) is a specialized region of the axon located at the junction between the somatodendritic and distal axonal domains that is essential for both action potential generation and the maintenance of neuronal polarity ([@bibr21-1759091417745426]; [@bibr6-1759091417745426]). This complex consists of cytoskeletal scaffolding proteins ankyrin-G (AnkG) and βIV-spectrin, which cluster the high density of voltage-gated ion channels required for action potential initiation and modulation ([@bibr26-1759091417745426]). The AIS is a highly dynamic and plastic structure regulated by changes in neuronal activity ([@bibr68-1759091417745426]), but its integrity is compromised consequential of a variety of pathological central nervous system (CNS) insults. These include models of epilepsy ([@bibr67-1759091417745426]; [@bibr20-1759091417745426]), ischemic injury ([@bibr54-1759091417745426]; [@bibr22-1759091417745426]), traumatic brain injury ([@bibr2-1759091417745426]; [@bibr17-1759091417745426]; [@bibr66-1759091417745426]), Alzheimer's disease ([@bibr30-1759091417745426]; [@bibr61-1759091417745426]; [@bibr35-1759091417745426]; [@bibr70-1759091417745426]), and multiple sclerosis (MS) ([@bibr19-1759091417745426]; [@bibr9-1759091417745426]). While the AIS is frequently and extensively targeted for disruption in CNS pathology, the mechanisms underlying altered stability of this domain have not been fully elucidated.

Our laboratory has previously demonstrated that AIS integrity is targeted for disruption in inflammatory environments. For example, induction of experimental autoimmune encephalomyelitis, a model commonly used to mimic the inflammatory component of MS ([@bibr28-1759091417745426]), resulted in severe disruption of the AIS domain, which was preceded by and correlated with microglial reactivity and increased contact ([@bibr9-1759091417745426]). Similarly, peripheral injection of lipopolysaccharide (LPS), a classic model of systemic inflammation, was sufficient to drive the loss of AIS protein clustering, which was reversed following resolution of the inflammatory response ([@bibr4-1759091417745426]). In both of these inflammatory models, treatment with Didox, a novel scavenger of reactive oxygen and nitrogen species (ROS/RNS) ([@bibr38-1759091417745426]; [@bibr65-1759091417745426]; [@bibr37-1759091417745426]), prevented and reversed the AIS pathology ([@bibr9-1759091417745426]; [@bibr4-1759091417745426]). In addition, LPS injection in mice deficient in the major ROS producing enzyme NADPH oxidase 2 ([@bibr47-1759091417745426]) resulted in the complete preservation of the AIS ([@bibr4-1759091417745426]). Together, these data highlight a potential role for ROS and RNS in the alteration of AIS protein clustering; however, direct evidence that ROS/RNS are capable of driving AIS disruption is lacking. Here, to address this void in our understanding, we investigate the effect of exogenously applied ROS/RNS on AIS stability in primary cortical neurons *in vitro*, utilizing the spontaneous ROS/RNS generator SIN-1 ([@bibr57-1759091417745426]).

Our findings demonstrate that oxidative stress, induced through exogenous application of ROS/RNS, is sufficient to drive structural disruption of the AIS protein complex. Pharmacological inhibition of voltage-dependent calcium channels (VDCCs), intracellular calcium (Ca^2+^) stores, and enzymatic activity suggests this mechanism of ROS/RNS-induced AIS disruption to involve cytosolic Ca^2+^ entry extracellularly through L-type VDCCs, and intracellularly from IP~3~-gated store release, as well as calpain protease activation.

Materials and Methods {#sec2-1759091417745426}
=====================

Animals {#sec3-1759091417745426}
-------

Timed pregnant embryonic Day 14 (E14) c57bl/6 mice were purchased from Charles River (Wilmington, MA) and maintained in the Virginia Commonwealth University Division of Animal Resources (VCU DAR) or the McGuire Veterans Affairs Medical Center (VAMC) vivariums, respectively, which are both AAALAC accredited facilities. Timed pregnant mice were maintained in the facilities until pups were removed on embryonic Day 15. Animals were maintained on an alternating 12-hr light and dark cycle and food and water were provided ad libitum. All procedures were conducted in accordance with the methods outlined in approved VCU and McGuire VAMC IACUC protocols.

Primary Neuronal Cultures {#sec4-1759091417745426}
-------------------------

Primary cortical neuron cultures were prepared from cerebral cortices of E15 mouse pups. Timed pregnant females were anesthetized with isoflurane and sacrificed by decapitation. Pups were removed and decapitated to allow for removal of the brains. Following removal of the meninges, cortices were incubated on ice in Accutase® Cell Detachment Solution (Innovative Cell Technologies, San Diego, CA) and dissociated step-wise using 1,000 -µL and 200 -µL sized pipette tips. Cells were counted and diluted in plating medium consisting of Neurobasal® medium (Thermo Fisher Scientific, Waltham, MA; Formulation detailed in Supplementary Table 1) supplemented with glutamate (25 µM, Sigma-Aldrich, St. Louis, MO), glutamine (0.5 mM, Thermo Fisher Scientific, Waltham, MA), Antibiotic-Antimycotic (Thermo Fisher Scientific, Waltham, MA), and B-27® supplement (Thermo Fisher Scientific, Waltham, MA). Cells were then plated at a density of 3000 cells/cm^2^ on poly-d-lysine (1 mg/mL; Sigma-Aldrich, St. Louis, MO)-coated glass coverslips (12 mm) in 24-well plates. Following cell attachment, wells were filled with the medium described above, in which the B-27® supplement was replaced with B-27® supplement minus antioxidants (Thermo Fisher Scientific, Waltham, MA). All experiments were performed starting at 12 days *in vitro* (DIV).

SIN-1 and Pharmacological Treatments {#sec5-1759091417745426}
------------------------------------

Twelve DIV neurons were treated with SIN-1 (3-Morpholinosydnonimine hydrochloride, Sigma-Aldrich, St. Louis, MO) diluted in the maintenance media described above at concentrations ranging from 0.1 to 100 μM and analyzed at 3, 6, 12, 24, or 72 hr posttreatment. All pharmacological reagents were added simultaneously with SIN-1 and included ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA) (0.001 to 2 mM), NiCl~2~ (0.1 to 50 μM), (S)-(−)-Bay K8644 (0.00001 to 50 μM), MK-801 (0.001 to 50 μM), 2-APB (0.1 to 50 μM), and FK-506 (0.001 to 50 μM) obtained from Sigma-Aldrich (St. Louis, MO), as well as ω-Conotoxin MVIIC (0.001 to 50 μM), nifedipine (0.001 to 50 μM), ryanodine (0.001 to 50 μM), and MDL 28170 (0.001 to 50 μM) obtained from Tocris Bioscience (Avonmouth, Bristol, England). Stock dilutions of all pharmacological reagents were prepared in DMSO (Thermo Fisher Scientific, Waltham, MA) with subsequent dilutions performed in culture medium, except for EGTA, NiCl~2~, and ω-Conotoxin MVIIC, in which all dilutions were performed in culture medium. While a larger concentration range of pharmacological inhibitors and activators was tested, only noncytotoxic concentrations were included in the presented data. All SIN-1 and pharmacological treatments were performed in three separate cell culture preparations (*n* = 3). Within each preparation, three technical replicates at the 24-hr time point were performed.

Measurement of Calpain Activity {#sec6-1759091417745426}
-------------------------------

Calpain activity was quantified using a fluorometric assay kit (Biovision, Milpitas, CA) according to the manufacturer\'s instructions. Briefly, neurons were treated with the extraction buffer provided by the manufacturer to extract cytosolic proteins while preventing the autoactivation of calpain during the extraction procedure. The neuronal supernatant was then incubated with a calpain substrate (Ac-LLY-AFC) which fluoresces at 505 nm upon cleavage. Fluorescence intensities at each SIN-1 concentration were measured on a spectrophotometric microplate reader and compared against an untreated sample at each time point. Six coverslips of neurons were pooled at each time point and SIN-1 concentration. Data from these measurements are presented as relative fluorescence units as a percent increase over untreated samples. A total of three separate culture preparations (*n* = 3), each run in three technical replicates, were compared at each measurement. Statistical comparisons were made by repeated measures one-way analysis of variance (ANOVA) with a Dunnett's multiple comparisons post hoc test. All graphing and statistical analyses were performed using GraphPad Prism version 6.03 for Windows (GraphPad Software, San Diego, CA).

Immunofluorescence {#sec7-1759091417745426}
------------------

Cells were immunolabeled with the appropriate primary and secondary antibodies (see below) as described previously ([@bibr56-1759091417745426]; [@bibr9-1759091417745426]; [@bibr4-1759091417745426]), with the modification that cells were fixed with 4% paraformaldehyde (Ted Pella, Redding, CA) for 5 min and permeabilized with ice cold methanol (Fisher Scientific, Waltham, MA). Slides were mounted with Vectashield™ mounting medium with DAPI (Vector Laboratories, Burlingame, CA) and imaged using confocal microscopy.

Antibodies {#sec8-1759091417745426}
----------

Axon initial segments were visualized using mouse monoclonal antibodies directed against AnkG (NeuroMab, Davis, CA; N106/36, 1:200) or βIV spectrin (a generous gift from Dr. Matthew Rasband, Baylor College of Medicine; 1:500). Neurons were identified using either NeuN (Millipore; Billerica, MA; 1:1000) or MAP2 (Sigma-Aldrich, St. Louis, MO; 1:500) antibodies. All secondary antibodies for immunofluorescence were purchased from Invitrogen Life Technologies (Grand Island, NY; Alexa™ Fluor) and used at a dilution of 1:500.

Confocal Microscopy or Quantitation {#sec9-1759091417745426}
-----------------------------------

### Image collection {#sec10-1759091417745426}

All images were collected using a Zeiss LSM 710 confocal laser scanning microscope (Carl Zeiss Microscopy, LLC, Thornwood, NY) housed in the VCU Department of Anatomy and Neurobiology Microscopy Facility. Confocal z-stacks, each spanning an optical distance of 10 µm, using a pin hole of 1 Airy disc unit and Nyquist sampling were collected from three technical replicate coverslips (12 mm) per treatment and time point resulting in 12 images per experimental group for AIS quantitation (∼ 600 neurons per treatment group). All comparisons were made using three independent culture preparations (*n* = 3). Images were taken with a 20× objective with a numerical aperture of 1.4; optical slice thickness was 0.49 µm, using a scan average of 2. X, Y, and Z image dimensions were 212.43 µm × 212.43 µm × 10.00 µm, respectively. The gain and offset values were kept constant for all images.

### AIS quantitation {#sec11-1759091417745426}

AIS stability was determined using ImageJ analysis software by manually counting initial segments from maximum intensity projection images resulting in the analysis of \>600 AISs per experimental treatment and time point. The number of neurons in a field of view (FOV) was also determined in the same images used for AIS analysis by counting NeuN-positive cells. Data are presented as the percent of NeuN-positive cells with an associated AIS as a percent of the control. One-way ANOVAs with Tukey's Honest Significant Difference post hoc tests were performed for these comparisons. All graphing and statistical analyses were performed using GraphPad Prism version 6.03 for Windows (GraphPad Software, San Diego, CA).

### Cell viability quantitation {#sec12-1759091417745426}

The extent of neuronal survival following SIN-1 treatment was determined using a propidium iodide (PI) exclusion assay. Prior to paraformaldehyde fixation, cells were treated with a 0.01-mg/mL PI (Molecular Probes, Eugene, OR) solution for 10 min. Cells were then fixed and immunolabeled for NeuN as described above. The number of PI-positive and NeuN-positive cells was manually counted from maximum intensity projection images using ImageJ analysis software. Data are presented as the percent of NeuN-positive cells negative for PI as a percent of the control (% neuronal survival). One-way ANOVAs with Tukey's Honest Significant Difference post hoc tests were performed for these comparisons. All graphing and statistical analyses were performed using GraphPad Prism version 6.03 for Windows (GraphPad Software, San Diego, CA).

### Measurement of ROS production {#sec13-1759091417745426}

Quantification of neuronal ROS production induced by SIN-1 treatment was performed using the CellROX® Green Reagent kit (Thermo Fisher Scientific, Walthanm, MA) according to the manufacturer\'s instructions. Briefly, 12 DIV primary cortical neurons grown on coverslips were treated with SIN-1 at concentrations ranging from 0.1 to 100 μM and analyzed 3, 6, 12, 24, or 72 hr posttreatment. Cells were incubated for 30 min at 37℃ with CellROX® reagent at a concentration of 5 μM. Coverslips were rinsed with PBS and mounted on slides with Vectashield™ hard-set mounting medium with DAPI (Vector Laboratories, Burlingame, CA), and imaged using confocal microscopy as described above. The CellROX® green fluorescence intensity was measured from maximum intensity projection images using ImageJ analysis software. Data from these measurements are presented as the percent fluorescence increase over the untreated at each SIN-1 treatment concentration and time point. Data from these measurements are presented as relative fluorescence units as a percent increase over untreated samples. A total of three separate culture preparations (*n* = 3) were compared at each measurement. Statistical comparisons were made by repeated measures one-way ANOVA with a Dunnett's multiple comparisons post hoc test. All graphing and statistical analyses were performed using GraphPad Prism version 6.03 for Windows (GraphPad Software, San Diego, CA).

Results {#sec14-1759091417745426}
=======

ROS/RNS Generator, SIN-1, Induces Primary Neuronal Oxidative Stress *In Vitro* {#sec15-1759091417745426}
------------------------------------------------------------------------------

To directly test the effect of ROS/RNS on AIS stability, we treated primary cortical neurons *in vitro* with the NO and superoxide donor SIN-1 ([@bibr57-1759091417745426]; [@bibr64-1759091417745426]; [@bibr51-1759091417745426]; [@bibr71-1759091417745426]). Optimal SIN-1 treatment conditions were first determined using a combination of cell death analysis and a ROS production assay to identify SIN-1 concentrations that generated ROS/RNS without inducing cortical neuron death. Our first step was to administer the SIN-1 reagent, ranging in concentrations from 0.1 µM to 100 µM consistent with previous studies ([@bibr64-1759091417745426]; [@bibr51-1759091417745426]; [@bibr71-1759091417745426]), to determine the maximum SIN-1 concentration that could be tolerated by the cultured cells. Neuronal survival was assessed by the PI exclusion assay 24 hr posttreatment, a time point consistent with previous SIN-1 cytotoxicity studies ([@bibr64-1759091417745426]). As shown in [Figure 1(a)](#fig1-1759091417745426){ref-type="fig"} to ([f](#fig1-1759091417745426){ref-type="fig"}) and (m), significant cell death was observed at the highest concentrations (50 µM and 100 µM), while no cell loss occurred at the concentrations of 25 µM and below. Specifically, the percent of NeuN positive cells that were also PI negative (defined as % neuronal survival) 24 hr after the addition of SIN-1 was 90.7% ± 6.6%, 84.0% ± 5.9%, 91.6% ± 4.9%, and 89.0% ± 9.5% for SIN-1 concentrations of 0.1, 1, 10, and 25 µM, respectively. Significant neuronal loss, however, was detected at SIN-1 concentrations of both 50 µM (54.4% ± 12.5%, *p* = .0004; [Figure 1(m)](#fig1-1759091417745426){ref-type="fig"}) and 100 µM (4.1% ± 0.42%, *p* \< .0001; [Figure 1(f)](#fig1-1759091417745426){ref-type="fig"} and ([m](#fig1-1759091417745426){ref-type="fig"})). Therefore, these findings indicated that 25 µM was an appropriate concentration for SIN-1 treatment to ensure that cell death was not induced. Figure 1.ROS/RNS generator, SIN-1, induces oxidative stress *in vitro*. Cortical neurons (NeuN+ cells, green) treated with ((b) to (f)) and without (a) SIN-1 at increasing concentrations reveal no propidium iodide (PI) staining at concentrations of 25 μM and below ((b) to (e)) 24 hr posttreatment; however, robust staining was present at concentrations of 50 μM (not shown) and 100 μM (f). Quantitation of percent neuronal survival, determined as the percentage of NeuN+ cells that were also PI- (as a percent of the untreated cells), revealed significant cell death at SIN-1 concentrations of 50 μM and 100 μM (m). The CellROXR Green assay for detection of ROS production by the cortical neurons revealed baseline levels of ROS at ≤6 hr post SIN-1 treatment ((g) to (i), (n)) with significantly elevated levels at 12 hr ((j) and (n)), peak levels at 24 hr ((k) and (n)) and a return to baseline by 72 hr ((l) and (n)). Asterisks represent a significant difference from the SIN-1 untreated group (\**p* \< .05).

Our initial studies to identify optimal SIN-1 concentrations were conducted at the 24-hr time point based on previous work ([@bibr64-1759091417745426]). However, to better understand the profile of ROS/RNS production in our culture system, we employed the CellROX® Green assay, a fluorogenic cell-permeable probe which fluoresces upon oxidation by ROS ([@bibr32-1759091417745426]; [@bibr24-1759091417745426]), to quantify levels of neuronal ROS over time. No significant increase in neuronal ROS levels was detected at 3 ([Figure 1(h)](#fig1-1759091417745426){ref-type="fig"} and ([n](#fig1-1759091417745426){ref-type="fig"})) and 6 hr ([Figure 1(i)](#fig1-1759091417745426){ref-type="fig"} and 9(n)) post SIN-1 treatment, at a concentration of 25 µM (the highest noncytotoxic concentration), as compared with the untreated cultures ([Figure 1(g)](#fig1-1759091417745426){ref-type="fig"} and ([n](#fig1-1759091417745426){ref-type="fig"})). However, by 12 hr ([Figure 1(j)](#fig1-1759091417745426){ref-type="fig"} and ([n](#fig1-1759091417745426){ref-type="fig"})) post SIN-1 addition, ROS levels were significantly increased with the levels peaking by 24 hr ([Figure 1(k)](#fig1-1759091417745426){ref-type="fig"} and ([n](#fig1-1759091417745426){ref-type="fig"})) post SIN-1 treatment. By 72 hr ([Figure 1(l)](#fig1-1759091417745426){ref-type="fig"} and ([n](#fig1-1759091417745426){ref-type="fig"})) post SIN-1 addition, ROS production returned to baseline levels indicating a resolution of the oxidative insult. With an established time course of SIN-1-induced oxidative stress through the CellROX® assay, we next asked whether AIS integrity was compromised as a result of this insult.

Exogenously Applied ROS/RNS Induce AIS Disruption *In Vitro* {#sec16-1759091417745426}
------------------------------------------------------------

To assess the effects of exogenously applied ROS/RNS on AIS stability, primary cortical neurons were treated with SIN-1 at all of the noncytotoxic concentrations tested above (0.1 to 25 µM) and subsequently double immunolabeled for AnkG and NeuN at 3, 6, 12, and 24 hr posttreatment. Data are presented as the percent of neurons (defined as NeuN+ cells) with an associated AIS (defined as AnkG+). Representative images for only the 25 µM SIN-1 treatments are shown for each time point ([Figure 2(b)](#fig2-1759091417745426){ref-type="fig"} to ([f](#fig2-1759091417745426){ref-type="fig"})). No significant alteration in AIS integrity was observed at any of the tested SIN-1 concentrations at (0.1 to 25 µM) 3 hr ([Figure 2(b)](#fig2-1759091417745426){ref-type="fig"} and ([g](#fig2-1759091417745426){ref-type="fig"})), 6 hr ([Figure 2(c)](#fig2-1759091417745426){ref-type="fig"} and ([h](#fig2-1759091417745426){ref-type="fig"})), or 12 hr ([Figure 2(d)](#fig2-1759091417745426){ref-type="fig"} and ([i](#fig2-1759091417745426){ref-type="fig"})) posttreatment as compared with the nontreated cultures ([Figure 2(a)](#fig2-1759091417745426){ref-type="fig"}). Similarly, at 24 hr ([Figure 2(j)](#fig2-1759091417745426){ref-type="fig"}), neither 0.1 µM nor 1 µM of SIN-1 was sufficient to induce disruption of the AIS. However, AIS loss was observed 24 hr after SIN-1 addition at concentrations of 10 µM ([Figure 2(j)](#fig2-1759091417745426){ref-type="fig"}; *p* = .034) and 25 µM ([Figure 2(e)](#fig2-1759091417745426){ref-type="fig"} and ([j](#fig2-1759091417745426){ref-type="fig"}); *p* = .003) with a significant reduction in the percent of neurons with an associated AIS of 29.0% ± 5.2% and 43.2% ± 3.7%, respectively. Results from AnkG quantitation were confirmed by immunolabeling for βIV-spectrin, another AIS protein crucial for domain stability (data not shown). Figure 2.Exogenous ROS/RNS drive disruption of the AIS *in vitro*. Axon initial segments of cultured cortical neurons maintain their integrity with no SIN-1 treatment (a) or 3 ((b) and (g)), 6 ((c) and (h)), or 12 ((d) and (i)) hr following exposure to 25 μM SIN-1, a concentration that did not induce cell death. However, at this same concentration, a significant dose-dependent reduction in the number of cortical neurons (NeuN+, green) that presented ankyrin-G (red) positive AISs was observed 24 hr after SIN-1 exposure (white arrows; (e) and (j)). By 72 hr post SIN-1 exposure, AIS integrity was restored ((f) and (k)) demonstrating the reversibility of AIS disruption and further indicating that AIS loss was not a consequence of cell death. Asterisks represent a significant difference from the SIN-1 untreated group (\**p* \< .05).

Since the CellROX® assay indicated a return to baseline levels of ROS/RNS by 72 hr, we next analyzed AIS integrity at this late time point to determine whether the ROS/RNS-induced AIS disruption is reversible. Interestingly, recovery was observed 72 hr following SIN-1 treatment at both the 10 µM ([Figure 2(k)](#fig2-1759091417745426){ref-type="fig"}) and 25 µM ([Figure 2(f)](#fig2-1759091417745426){ref-type="fig"} and ([k](#fig2-1759091417745426){ref-type="fig"})) concentrations. To ensure that the recovery in the percentage of AIS+ cells was not due to a loss of neurons that lacked positively labeled AISs, the relative number of NeuN+ cells was compared between the treated and nontreated groups. No significant difference was observed between groups (data not shown) indicating that NeuN+ cells that lost their AISs did not die, but recovered from the SIN-1 treatment and restored their AIS. This recovery at 72 hr posttreatment corresponds to a return to baseline of neuronal ROS levels as shown in [Figure 1(l)](#fig1-1759091417745426){ref-type="fig"} and ([n](#fig1-1759091417745426){ref-type="fig"}). Overall, these data provide a time course for ROS/RNS-induced AIS disruption in our *in vitro* system, allowing for subsequent pharmacological manipulations to elucidate the underlying mechanism. All further experiments were performed 24 hr following treatment of 25 µM SIN-1, the time point of peak AIS loss, and the highest noncytotoxic concentration of SIN-1, respectively.

ROS/RNS-Induced AIS Disruption Requires Extracellular Ca^2+^ {#sec17-1759091417745426}
------------------------------------------------------------

Calcium (Ca^2+^) is central to most previously identified mechanisms of AIS modulation, during both activity-dependent plasticity ([@bibr68-1759091417745426]) as well as pathological insult ([@bibr59-1759091417745426]). To determine if ROS/RNS-induced AIS disruption involves extracellular Ca^2+^ entry, neurons were pretreated with the nonmembrane permeable Ca^2+^-chelating agent EGTA, prior to SIN-1 addition. EGTA pretreatment at concentrations of 0.001 mM and 0.01 mM were not sufficient to prevent the AIS disruption previously observed ([Figure 3(d)](#fig3-1759091417745426){ref-type="fig"}), and SIN-1 treated cells exposed to these concentrations were indistinguishable from those without EGTA ([Figure 3(b)](#fig3-1759091417745426){ref-type="fig"} and ([d](#fig3-1759091417745426){ref-type="fig"})). EGTA concentrations of 1 mM ([Figure 3(d)](#fig3-1759091417745426){ref-type="fig"}) and 2 mM ([Figure 3(c)](#fig3-1759091417745426){ref-type="fig"} and ([d](#fig3-1759091417745426){ref-type="fig"})), however, were capable of attenuating the AIS disruption, resulting in the preservation of 81.9% ± 0.8% (*p* = .0004) and 94.9% ± 0.7% (*p* \< .0001) of neurons with an associated AIS, respectively, as compared with the 62.3% ± 1.6% observed with SIN-1 treatment alone. Similar to other previously established models of AIS plasticity and injury ([@bibr54-1759091417745426]; [@bibr59-1759091417745426]; [@bibr68-1759091417745426]), these data demonstrate that extracellular Ca^2+^ is central to AIS disruption; however, we implicate ROS/RNS as upstream activators of this degenerative pathway. Figure 3.ROS/RNS-induced AIS disruption is attenuated following chelation of extracellular Ca^2+^. The loss of AIS labeling (white arrows) following exposure to 25 μM SIN-1 (b) was inhibited by the addition of EGTA (c) to the medium prior to SIN-1 treatment. The extent of AIS maintenance was directly dependent on the dose of EGTA (d). An asterisk with an associated bracket indicates significant differences between treated groups; asterisks without an associated bracket represent a significant difference from the SIN-1 untreated group (a, \**p* \< .05). NeuN, green; AnkG, red.

L-Type Voltage-Dependent Calcium Channels Are Required for ROS/RNS-Induced AIS Disruption {#sec18-1759091417745426}
-----------------------------------------------------------------------------------------

While the importance of extracellular Ca^2+^ entry has been demonstrated with EGTA, the entry point for Ca^2+^ into the cell during ROS/RNS-induced AIS modulation remains unclear. To address this, we pretreated neurons with a series of inhibitors to the known types of voltage-dependent calcium channels prior to SIN-1 treatment ([@bibr8-1759091417745426]). Inhibition of T- and R-type VDCCs by NiCl~2~ ([@bibr5-1759091417745426]; [@bibr14-1759091417745426]) revealed no significant attenuation of SIN-1-induced AIS disruption at the range of concentrations tested (0.1 to 50 µM; [Figure 4(c)](#fig4-1759091417745426){ref-type="fig"} and ([g](#fig4-1759091417745426){ref-type="fig"})). Similarly, no AIS protection was observed following application of the P-, Q-, and N-type VDCC inhibitor ω-Conotoxin MVIIC (0.0001 to 1 µM; [Figure 4(d)](#fig4-1759091417745426){ref-type="fig"} and ([h](#fig4-1759091417745426){ref-type="fig"})). Concentrations of these inhibitors higher than those presented resulted in significant neuronal death (data not shown). In addition, specific inhibition of L-type VDCCs with nifedipine ([@bibr43-1759091417745426]) at concentrations of 0.001 to 0.1 µM was not sufficient to protect AIS integrity. However, attenuation of SIN-1-induced AIS disruption was observed following pretreatment with the L-type specific VDCC inhibitor at concentrations of 1 µM and 10 µM ([Figure 4(e)](#fig4-1759091417745426){ref-type="fig"} and ([i](#fig4-1759091417745426){ref-type="fig"})) resulting in the preservation of 88.3% ± 3.66% (*p* = .0147) and 92.1% ± 4.3% (*p* = .0055) of AISs respectively, as compared with the 60.2% ± 3.9% percent observed with SIN-1 treatment alone. Figure 4.L-type voltage-dependent calcium channels are required for ROS/RNS-induced AIS disruption. Similar to SIN-1 treated neurons without inhibitor pretreatment (b), neurons (NeuN+, green) treated with inhibitors directed against T/R- ((c) and (g)) or P/N/Q-type ((d) and (h)) calcium channels prior to SIN-1 exposure presented with significant loss (white arrows) in AIS labeling (AnkG, red). In contrast, cultured cortical neurons treated with an L-type calcium channel inhibitor ((e) and (i)) resulted in a significant preservation of the AISs. Further demonstrating a role for L-type calcium channels in mediating AIS alterations, cortical neurons treated with (S)-(-)-Bay K 8644 also resulted in a significant disruption of the AISs ((f) and (j)). Asterisks without an associated bracket represent a significant difference from the SIN-1 untreated group (a, \**p* \< .05).

We then asked whether Ca^2+^ flow through L-type VDCCs in the absence of SIN-1 was sufficient to drive disruption of the AIS. To address this, a selective irreversible activator of L-type channels, (S)-(-)-Bay K 8644 ([@bibr49-1759091417745426]; [@bibr16-1759091417745426]), was used at concentrations ranging from 0.00001 to 1 µM with AIS assessment performed 24 hr posttreatment. This treatment resulted in a significant reduction in the percent of neurons with an associated AIS at concentrations of 0.1 µM and 1 µM by 22.6% ± 3.9% (*p* = .0002) and 32.5% ± 3.9% (*p* \< .0001), respectively ([Figure 4(f)](#fig4-1759091417745426){ref-type="fig"} and ([j](#fig4-1759091417745426){ref-type="fig"})). Importantly, these concentrations of (S)-(-)-Bay K 8644 did not result in neuronal death as determined by the PI exclusion assay described above (data not shown). Overall, these data suggest that ROS/RNS-mediated disruption of the AIS involves extracellular Ca^2+^ flow specifically through L-type VDCCs, and that activation of these channels, independently of SIN-1, is sufficient to drive similar AIS alterations.

ROS/RNS-Mediated AIS Modulation Involves IP~3~-Gated Ca^2+^ Stores {#sec19-1759091417745426}
------------------------------------------------------------------

Because AIS stability is heavily dependent on the level of intracellular Ca^2+^ ([@bibr59-1759091417745426]; [@bibr68-1759091417745426]) and on the function of VDCCs for ROS/RNS-mediated AIS disruption, we next asked if release from intracellular stores is involved in this SIN-1-induced insult. Prior to SIN-1 addition, neurons were pretreated with inhibitors to both ryanodine and inositol 1,4,5-trisphosphate (IP~3~) receptors, the two major mediators of Ca^2+^ release from intracellular stores ([@bibr36-1759091417745426]; [@bibr14-1759091417745426]). Inhibition of ryanodine receptors with ryanodine at concentrations of 0.001 to 10 µM did not result in protection of the AIS from SIN-1-induced disruption ([Figure 5(c)](#fig5-1759091417745426){ref-type="fig"} and ([e](#fig5-1759091417745426){ref-type="fig"})). Concentrations greater than 10 µM resulted in significant neuronal death (data not shown). Conversely, pretreatment with IP~3~ receptor inhibitor 2-Aminoethoxydiphenyl borate (2-APB) was capable of significantly preserving AIS integrity in a dose-dependent manner at concentrations of 10 µM and 20 µM, resulting in the preservation of 80.4% ± 7.3% (*p* = .0290) and 95.1% ± 2.7% (*p* = .0002) of neurons with an intact AIS, respectively ([Figure 5(d)](#fig5-1759091417745426){ref-type="fig"} and ([f](#fig5-1759091417745426){ref-type="fig"})). Interestingly, low concentrations of 2-APB (\<10 µM) result in the release of Ca^2+^ from IP~3~-gated intracellular stores ([@bibr11-1759091417745426]), a possible explanation for the exacerbated effect of SIN-1 on the AIS at the 0.1 µM concentration ([Figure 5(f)](#fig5-1759091417745426){ref-type="fig"}; *p* = .0010). Taken together, these data highlight an important role for Ca^2+^ release from IP~3~, but not ryanodine-sensitive intracellular stores in ROS/RNS-induced AIS disruption. Figure 5.IP~3~-gated Ca^2+^ stores are required for ROS/RNS-induced AIS disruption. AIS labeling (AnkG, red) was lost (white arrows) following exposure of cortical neurons (NeuN+, green) to 25 μM SIN-1 (b). This disruption was prevented by pretreatment with an IP~3~-receptor inhibitor ((d) and (f)) but not an inhibitor to ryanodine receptors ((c) and (e)). Asterisks without an associated bracket represent a significant difference from the SIN-1 untreated group (a, \**p* \< .05).

Calpain, but Not Calcineurin Activity, Is Involved in ROS/RNS-Induced AIS Disruption {#sec20-1759091417745426}
------------------------------------------------------------------------------------

While Ca^2+^ from both extracellular and intracellular sources appears to play a critical role in ROS/RNS-mediated AIS disruption, the downstream mediator of this AIS modulation remains unknown. Previously described mechanisms of AIS plasticity and injury have implicated two Ca^2+^-activated enzymes as critical regulators of AIS stability ([@bibr54-1759091417745426]; [@bibr14-1759091417745426]). These include calcineurin, a Ca^2+^-activated phosphatase responsible for disassembly of the AIS protein complex in models of activity-dependent plasticity ([@bibr14-1759091417745426]), as well as calpain, a Ca^2+^-activated protease whose substrates include critical structural and functional AIS proteins ([@bibr54-1759091417745426]). To assess the contribution of each potential AIS modulator in ROS/RNS-induced AIS disruption, pharmacological inhibitors of each were employed prior to SIN-1 addition. Inhibition of calcineurin with FK-506 ([@bibr14-1759091417745426]) in the presence of SIN-1 was insufficient to prevent AIS disruption at all concentrations tested (0.001 to 10 μM; [Figure 6(c)](#fig6-1759091417745426){ref-type="fig"} and ([e](#fig6-1759091417745426){ref-type="fig"})). Concentrations greater than 10 µM resulted in significant neuronal death (data not shown). Figure 6.ROS/RNS-induced AIS disruption is mediated by calpain but not calcineurin activity. Cultured cortical neurons (NeuN+, green) treated with an inhibitor directed against calcineurin ((c) and (e)) prior to SIN-1 exposure presented with a significant loss (white arrows) of AIS labeling (AnkG, red) similar to the SIN-1 treated neurons without inhibitor pretreatment (b). In contrast, neurons treated with a calpain inhibitor displayed a significant preservation of AISs ((d) and (f)). A calpain protease activity assay revealed significantly elevated activity at 12 hr, peak activity at 24 hr, and a return to baseline by 72 hr post SIN-1 treatment (25 μM) which is represented as the percent increase over untreated neurons (g). Asterisks without an associated bracket represent a significant difference from the SIN-1 untreated group (a, \**p* \< .05).

Treatment with the well-established calpain inhibitor MDL 28170 ([@bibr54-1759091417745426]; [@bibr13-1759091417745426]), however, prevented AIS loss in a dose-dependent manner, at concentrations of 1 μM and 10 μM, yielding preservation of 83.3% ± 0.6% (*p* \< .0001) and 96.8% ± 0.8% (*p* \< .0001) of AISs, respectively ([Figure 6(d)](#fig6-1759091417745426){ref-type="fig"} and ([f](#fig6-1759091417745426){ref-type="fig"})). A fluorescent activity assay was used to determine the time course of calpain activity, at the time points tested in [Figure 2](#fig2-1759091417745426){ref-type="fig"}, in order to correlate with SIN-1-induced AIS loss and recovery. While elevated calpain activity was observed at 12 hr post SIN-1 treatment (69.4% ± 4.8% increase over untreated; *p* = .0036; [Figure 6(g)](#fig6-1759091417745426){ref-type="fig"}), peak activity was observed at 24 hr (255.5% ± 14.9% increase over untreated; *p* \< .0001; [Figure 6(g)](#fig6-1759091417745426){ref-type="fig"}); the time point at which AIS loss is greatest ([Figure 2(e)](#fig2-1759091417745426){ref-type="fig"} and ([j](#fig2-1759091417745426){ref-type="fig"})). Interestingly, by 72 hr post SIN-1 treatment, calpain activity returned to baseline levels (34% ± 9.9% increase over untreated; [Figure 6(g)](#fig6-1759091417745426){ref-type="fig"}), corresponding to the point at which neuronal ROS levels returned to baseline ([Figure 1(l)](#fig1-1759091417745426){ref-type="fig"} and ([n](#fig1-1759091417745426){ref-type="fig"})) and AIS recovery is achieved ([Figure 2(f)](#fig2-1759091417745426){ref-type="fig"} and ([k](#fig2-1759091417745426){ref-type="fig"})). Overall, these data implicate a role for calpain, but not calcineurin, as an effector of AIS disruption downstream of oxidative stress.

Discussion {#sec21-1759091417745426}
==========

Previous work from our lab implicated oxidative stress as a mediator of AIS disruption, since free radical scavenger treatment was sufficient to protect and recover the domain in an inflammatory mouse model of MS ([@bibr9-1759091417745426]). In addition, ablation of NOX2, a major source of ROS/RNS production in the CNS, was sufficient to preserve AIS integrity in an LPS model of systemic inflammation ([@bibr4-1759091417745426]). While these studies suggested a role for oxidative stress in AIS modulation, the direct effects of reactive oxygen and nitrogen species on AIS stability remained unclear. The present study demonstrates for the first time that oxidative stress, induced through exogenous ROS/RNS application, drives structural alterations of the AIS. In addition, pharmacological inhibition of both voltage-dependent and intracellular Ca^2+^ channels suggests that Ca^2+^ entry through L-type VDCCs and its release from IP~3~-gated stores are involved in ROS/RNS-mediated AIS modulation. Furthermore, this AIS insult is dependent upon calpain, but not calcineurin, activity.

The Role of ROS/RNS in Axonal Pathology {#sec22-1759091417745426}
---------------------------------------

The data presented in this study highlight a role for ROS/RNS in disruption of the AIS protein complex, but other axonal targets of oxidative stress have been described. These include the F-actin cytoskeleton ([@bibr23-1759091417745426]; [@bibr72-1759091417745426]), axonal growth cones ([@bibr40-1759091417745426]; [@bibr41-1759091417745426]), and microtubule-associated stabilizers and motors ([@bibr60-1759091417745426]; [@bibr7-1759091417745426]; [@bibr50-1759091417745426]). Reactive oxygen and nitrogen species have also been associated with the pathogenesis of many CNS insults including axonal loss in peripheral nerve and spinal cord injury ([@bibr29-1759091417745426]; [@bibr34-1759091417745426]), hyperphosphorylation of tau in Alzheimer's disease ([@bibr55-1759091417745426]), loss of cortical connections following ischemia ([@bibr52-1759091417745426]), and demyelination and axonal degeneration in MS ([@bibr15-1759091417745426]; [@bibr48-1759091417745426]).

Because oxidative stress is a key contributor to many CNS pathologies ([@bibr31-1759091417745426]; [@bibr58-1759091417745426]; [@bibr39-1759091417745426]; [@bibr25-1759091417745426]), it is likely that this mechanism of ROS/RNS-induced AIS modulation may underlie many models of CNS injury. Our laboratory has recently identified AIS disruption in both an inflammatory model of MS ([@bibr9-1759091417745426]), as well as a model of systemic inflammation ([@bibr4-1759091417745426]), which was prevented or reversed upon free-radical scavenger treatment. In addition, other labs have reported alterations in AIS stability in models of epilepsy ([@bibr67-1759091417745426]; [@bibr20-1759091417745426]), ischemic injury ([@bibr54-1759091417745426]; [@bibr22-1759091417745426]), traumatic brain injury ([@bibr2-1759091417745426]; [@bibr17-1759091417745426]; [@bibr66-1759091417745426]), and Alzheimer's disease ([@bibr30-1759091417745426]; [@bibr61-1759091417745426]; [@bibr35-1759091417745426]; [@bibr70-1759091417745426]), which have all been shown to be associated with CNS oxidative stress through ROS/RNS dysregulation ([@bibr31-1759091417745426]; [@bibr58-1759091417745426]; [@bibr39-1759091417745426]; [@bibr25-1759091417745426]).

ROS/RNS and Ca^2+^ Entry {#sec23-1759091417745426}
------------------------

Our data suggest that ROS/RNS-mediated AIS disruption involves extracellular Ca^2+^ entry through L-type VDCCs, as well as intracellular release from IP~3~-gated stores. While the mechanistic link between ROS/RNS application and cytosolic Ca^2+^ levels is not well defined in our system, previous studies examining this link may provide insight. Similar to the present study, SIN-1 treatment is known to induce Ca^2+^ entry through L-type channels in CA1 pyramidal neurons, cardiomyocytes, and striatal neurons ([@bibr46-1759091417745426]; [@bibr51-1759091417745426]; [@bibr71-1759091417745426]). Peroxynitrite treatment of cerebral cortical neurons, the cell type used in the present study, also resulted in increased Ca^2+^ entry through L-type VDCCs ([@bibr45-1759091417745426]). However, the effects of SIN-1 have been shown to vary in other cell types, as treatment resulted in decreased Ca^2+^ flow through L-type VDCCs in cerebellar granule cells and vestibular hair cells ([@bibr18-1759091417745426]; [@bibr1-1759091417745426]; [@bibr63-1759091417745426]). While the mechanism of ROS/RNS modulation of L-type VDCCs remains unclear for most cell types described, S-glutathionylation of the L-type VDCCs has been shown to be involved in increased Ca^2+^ flow through these channels in cardiomyocytes ([@bibr62-1759091417745426]; [@bibr27-1759091417745426]). It remains to be determined if this, or other modifications, could underlie SIN-1-induced Ca^2+^ influx through L-type VDCCs in our primary cortical neuron system.

In addition to L-type VDCCs, we demonstrate the involvement of IP~3~-gated intracellular Ca^2+^ stores on ROS/RNS-induced AIS disruption. Similar to the present study, previous work has shown SIN-1 and its ROS/RNS products to induce release of Ca^2+^ specifically through IP~3~-gated stores in neuroblastoma SH-SY5Y cells and cardiomyocytes ([@bibr53-1759091417745426]; [@bibr10-1759091417745426]). It has been reported, however, that SIN-1-derived ROS/RNS can induce intracellular Ca^2+^ release nonspecifically in renal epithelial cells and ventral horn spinal cord neurons ([@bibr44-1759091417745426]; [@bibr42-1759091417745426]) or specifically through ryanodine-sensitive stores in smooth and skeletal muscle cells ([@bibr46-1759091417745426]; [@bibr69-1759091417745426]). Given the cell-type specific effects of ROS/RNS on both voltage-dependent and intracellular Ca^2+^ channel function reported in the literature, the mechanistic action of SIN-1 on L-type VDCCs and IP~3~-gated intracellular stores in our system remains to be determined.

How Does Calpain Modulate the AIS? {#sec24-1759091417745426}
----------------------------------

In the present study, we have identified ROS/RNS-induced AIS disruption to be dependent upon calpain activation. Similarly, calpain activity has been shown to drive AIS alterations in other model systems including ischemic injury ([@bibr54-1759091417745426]), glutamate excitotoxicity ([@bibr3-1759091417745426]), and P2X7 purinergic activation ([@bibr12-1759091417745426]). [@bibr54-1759091417745426] demonstrated that proteolytic degradation of essential AIS proteins, such as ankyrinG, βIV spectrin, and voltage-gated Na^+^ channels, was the mechanism underlying calpain-mediated AIS modulation following ischemic injury. [@bibr3-1759091417745426] and [@bibr12-1759091417745426] did not analyze the extent of proteolysis, but speculated that a mechanism similar to that reported by [@bibr54-1759091417745426] was most likely involved in their models of AIS injury. It is likely that calpain-mediated proteolysis of the AIS complex underlies the alterations observed following the ROS/RNS-induced insult presented in this study, as this mechanism is well characterized by [@bibr54-1759091417745426].

In summary, for the first time, we demonstrate that oxidative stress, stimulated directly through exogenously applied ROS/RNS, is capable of reversible structural modulation of the AIS. This mechanism involves activity of L-type VDCCs, as well as intracellular IP~3~-gated stores. In addition, calpain, but not calcineurin, activity is involved in this ROS/RNS-induced disruption. These findings provide new insights into the mechanisms underlying altered AIS stability in a variety of CNS pathologies.

Summary {#sec25-1759091417745426}
=======

Oxidative stress, stimulated through the exogenous application of reactive oxygen and nitrogen species, drives structural disruption of the axon initial segment through a Ca^2+^ and calpain-dependent mechanism.

The authors wish to thank Dr. Matthew Rasband, Professor in the Department of Neuroscience, Baylor College of Medicine, for his generous gift of the βIV spectrin antibody.

Declaration of Conflicting Interests {#sec26-1759091417745426}
====================================

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding {#sec28-1759091417745426}
=======

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by a Veterans Affairs Merit Award (5IO1BX002565). Microscopy was performed at the Virginia Commonwealth University --Department of Anatomy and Neurobiology Microscopy Facility, supported, in part, with funding from NIH-NINDS Center core grant (5P30NS047463).

Supplemental Material {#sec27-1759091417745426}
=====================

Supplementary material is available for this article online.
